Immunotherapy and Cell Therapy at AACR 2026: What Cancer Patients Should Know

From CAR-T cells that don't burn out to vaccines that protect for 6 years — the next generation of immune-based cancer treatments.

Published April 26, 2026 • 10 min read

TL;DR: AACR 2026 showcased breakthroughs that could reshape cancer immunotherapy: a new type of CAR-T cell (KIR-CAR) that resists exhaustion in solid tumors, an mRNA injection that programs your body to make cancer-fighting bispecific antibodies (100% response rate, zero serious side effects), a personalized cancer vaccine with 87.5% of responders alive at 6 years, and the first patient treated with "in vivo" CAR engineering — no cell manufacturing needed. Many of these are in clinical trials now.

What Changed at AACR 2026?

Checkpoint immunotherapy (drugs like pembrolizumab and nivolumab) transformed cancer treatment over the past decade. But many patients don't respond, and those who do often eventually progress. AACR 2026 presented the next wave of immunotherapy — approaches that go beyond simply "releasing the brakes" on the immune system to actively engineering immune cells to fight cancer.

CAR-T Cells That Don't Burn Out: KIR-CAR

CAR-T cell therapy has been transformative for blood cancers (leukemia, lymphoma), but has largely failed in solid tumors like lung, breast, and ovarian cancer. The main reason: T cell exhaustion. CAR-T cells get "burned out" by the hostile tumor environment and stop working.

KIR-CAR T cells (Verismo Therapeutics) solve this by borrowing biology from NK cells (natural killer cells). Instead of the "always-on" signaling that causes exhaustion, KIR-CAR uses a natural on/off switching mechanism. In the first clinical trial (STAR-101), 9 patients with ovarian cancer, mesothelioma, and cholangiocarcinoma were treated — with no dose-limiting toxicities, only mild side effects, and one patient achieving an ongoing response beyond 6 months.

This is early data, but it's the first clinical proof that redesigning the CAR architecture itself — not just picking a better target — can overcome the solid tumor barrier.

mRNA Bispecific Antibodies: Your Body Makes the Drug

One of the most striking presentations was ABO2203 (Abogen) — an mRNA injection that programs your body's cells to produce a cancer-fighting bispecific antibody.

Instead of manufacturing a complex protein in a factory and infusing it into patients, a simple subcutaneous injection delivers mRNA in a lipid nanoparticle. Your cells read the mRNA instructions and produce the bispecific antibody continuously for about a week.

Results in 9 patients with relapsed B-cell lymphoma:

The zero CRS is remarkable — likely because the drug builds up gradually (the body makes it slowly) rather than being infused all at once. If validated in larger trials, this approach could eventually be applied to solid tumor targets.

Cancer Vaccines: 6-Year Protection

Personalized cancer vaccines have been a promise for decades. At AACR 2026, we saw the strongest evidence yet that they actually work — and work durably.

Autogene cevumeran (BNT122), a personalized mRNA neoantigen vaccine developed by BioNTech and Memorial Sloan Kettering, showed 6-year follow-up data in pancreatic cancer patients after surgery. 87.5% of vaccine responders were still alive at 6 years — compared to 25% of non-responders. The immune memory T cells generated by the vaccine were still active and functional even after subsequent chemotherapy.

This matters for patients because it shows personalized vaccines can create durable immune protection — not just a temporary boost. Trials are expanding to other cancer types.

PD-1/VEGF Bispecifics: The Next Keytruda?

Four companies are racing to develop bispecific antibodies that block both PD-1 (immune checkpoint) and VEGF (blood vessel growth) in a single molecule — potentially replacing pembrolizumab (Keytruda) as first-line treatment:

DrugResponse Rate (1L NSCLC)Stage
SSGJ-707 (3SBio/Pfizer)62%Phase 2
MK-2010 (Merck)55%Phase 1/2
Ivonescimab (Akeso/Summit)50%BLA accepted by FDA
Pumitamig (BioNTech/BMS)47%Phase 2

These response rates in first-line lung cancer are competitive with or better than current pembrolizumab combinations. Ivonescimab is the most advanced, with FDA application already accepted. Trials are also expanding to other cancers including breast (TNBC), gastric, and liver cancer.

In Vivo CAR Engineering: No Manufacturing Needed

Traditional CAR-T therapy requires extracting a patient's blood, shipping cells to a factory, engineering them over weeks, and re-infusing them — at a cost of $400,000+. In vivo CAR engineering skips all of this.

MT-304 (CREATE Medicines) is the first in vivo CAR therapy to reach patients. An mRNA-lipid nanoparticle injection programs the patient's own NK cells and immune cells to become CAR cells directly inside the body. No cell extraction, no manufacturing, no lymphodepletion chemotherapy — and the treatment can be repeated.

Even more futuristic: CREATE's RetroT platform uses all-RNA genome integration to create stable CAR expression without viral vectors — a potential path to permanent in vivo CAR engineering.

TCR-T Cell Therapy: Reaching Inside Cancer Cells

While CAR-T targets proteins on the cell surface, TCR-T therapy targets proteins inside cancer cells — greatly expanding what can be attacked. At AACR 2026, a remarkable case was presented:

A 17-year-old with advanced metastatic kidney cancer (tumors in lungs, liver, and brain) who had exhausted all standard treatments received IMA203CD8, a TCR-T therapy targeting PRAME. At 6 months: deep regression across all sites, no detectable tumor DNA in blood (molecular remission), and the patient in "excellent physical condition."

PRAME is expressed across many solid tumors. The FDA-approved TCR-T therapy afami-cel (Tecelra) for synovial sarcoma showed 39% response rates, and is now expanding to other MAGE-A4-positive cancers. TCR-T trials are actively recruiting.

What This Means for Patients Seeking Trials

Find Immunotherapy Trials for Your Cancer

Disease-Specific Trial Pages

Browse recruiting trials for cancers with active immunotherapy and cell therapy research:

This article summarizes publicly presented data from the AACR 2026 Annual Meeting (April 2026, Chicago). It is intended for educational purposes and does not constitute medical advice. Always discuss treatment options with your oncologist. See also: ADC Therapies at AACR 2026.